AbbVie, Inc. (ABBV)

84.34
NYSE
Prev Close 84.31
Day Low/High 83.94 / 85.15
52 Wk Low/High 62.55 / 101.28
Exchange NYSE
Shares Outstanding 1764.83B
Market Cap 148.79B
P/E Ratio 72.63
Div & Yield N.A. (N.A)
Futures Mixed in Reaction to Int'l Headlines; AbbVie, Shire Deal

Futures Mixed in Reaction to Int'l Headlines; AbbVie, Shire Deal

The futures markets are mixed this morning as news of the Malaysian Airlines plane shot down in the Ukraine and tensions in Gaza dominate investors minds.

This Morning's Market Setup

Where it began. The rundown: U.S. futures are higher this morning (S&P up 6 handles, Nasdaq up 18 handles). European stocks are climbing, too (by about 0.8%). Nikkei is up 0.88%. Within the Nikkei, all major sub-groups finished in the green. Telecom...

Abbvie upgraded at Morgan Stanley

Spend Is a Four-Letter Word

Spend Is a Four-Letter Word

The market wants companies that are taking share with minimal spending.

Gilead Sciences: A Top Pick Update

Gilead Sciences: A Top Pick Update

Investors may be worried about Sovaldi's price.

Miracle Drug May Be Ailing Gilead

Miracle Drug May Be Ailing Gilead

Its potent hepatitis C treatment is not a boon for shareholders.

Dividend D-Day Coming

Dividend D-Day Coming

The goal is always simply to get out where we got in.

AbbVie price target lowered at Jefferies

Abbvie downgraded at Morgan Stanley

Abbvie upgraded at BMO

A Billionaire's Dividend Picks

A Billionaire's Dividend Picks

Here's what Glen Dubin's Highbridge funds have been buying.

Small Fund Managers Deliver Big

Small Fund Managers Deliver Big

They can spend a lot of time analyzing their picks.

Abbvie estimates, target upped at BMO

Off the Charts

Off the Charts

Maintain a long-side bias until composure changes.

Biotech's Next Big Thing: Merck

Biotech's Next Big Thing: Merck

Alzheimer drugs with a focus on Merck will be on investors minds in the coming week, says Adam Feuerstein, Sr. Columnist at TheStreet.

USAA: AbbVie, Google Offer Growth

USAA: AbbVie, Google Offer Growth

John Toohey, PM of the USAA First Start Growth Fund, names his top stocks including AbbVie, Thermo Fisher, Google and Texas Instruments.

Paul Tudor Jones Loves Pharma Spinoffs

The billionaire's hedge fund bought heavily into this theme in the first quarter.

Keeping an Eye on the Pros

Keeping an Eye on the Pros

Today's investment environment has more moving parts than ever.

Rules of the Game: Identifying Growth Stocks

Rules of the Game: Identifying Growth Stocks

The objective of investing is to offset future liabilities and manage risk.

National Lemming Day

National Lemming Day

It's the only thing that explains today's action.

Abbvie upgraded at Morgan Stanley

Health Care Stocks Still Promising

Health Care Stocks Still Promising

Plenty of leadership remains in the health care sector and there's reason to see further potential.

Diary of a Dividend Diva: In the Doldrums

Diary of a Dividend Diva: In the Doldrums

Pickings are slim this month but get prepared for the deluge coming in May.

Betting on Youth

Betting on Youth

These recent IPOs offer noteworthy returns.

Abbvie downgraded at BMO

AbbVie numbers raised at Jefferies

Abbvie estimates, target boosted at BMO

How Much to Buy?

$2.1 billion. "One last thing." -- Lt. Columbo My mavens on the floor see $2.1 billion to buy on the close. Financials have $490 million to buy, energy $300 million to buy, consumer staples $300 million to buy and health care $250 million to buy. In...